Development asset linked to Pierre Fabre Medical in public FDA and regional records.
pharma · sickle cell anaemia · Chronic Obstructive Pulmonary Disease
Pierre Fabre Medical
Pierre Fabre Australia Pty Ltd
Pierre Fabre Medical drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
North Sydney, AU HQ
2002 Founded
5 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- North Sydney, AU
- Founded
- 2002
- Employees
- 5
- Programs
- 3
- Drugs
- 18
- Patents
- 0
Pierre Fabre Medical pipeline
Portfolio lens on 18 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pierre Fabre Medical drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
binimetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
encorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.
- Target
- Serine/threonine-protein kinase B-raf
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
human papillomavirus 9-valent vaccine (recombinant, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Pierre Fabre Medical's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Pierre Fabre Medical's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
lidocaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
Development asset linked to Pierre Fabre Medical in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor